Application
Fig1: Western blot analysis of Cytokeratin 5 on A431 cells lysates using anti-Cytokeratin 5 antibody at 1/1,000 dilution.Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.Application
Fig3: Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.Application
Fig4: Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.| Product Name | Cytokeratin 5 [SC62-04] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | 58 kDa cytokeratin antibody CK-5 antibody CK5 antibody Cytokeratin-5 antibody Cytokeratin5 antibody DDD antibody DDD1 antibody EBS2 antibody epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody K2C5_HUMAN antibody K5 antibody keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) antibody Keratin 5 antibody Keratin antibody keratin complex 2, basic, gene 5 antibody keratin, type II cytoskeletal 5 antibody Keratin-5 antibody Keratin5 antibody KRT 5 antibody Krt5 antibody KRT5A antibody type II cytoskeletal 5 antibody Type-II keratin Kb5 antibody |
| Product description | Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. Cytokeratins have been found to be useful markers of tissue differentiation which is directly applicable to the characterization of malignant tumors. Cytokeratin 5 is expressed in normal basal cells. Mutations of the cytokeratin 5 gene (KRT5) have been shown to result in the autosomal dominant disorder epidermolysis bullosa (EB). |
| Immunogen | recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Host Species | Recombinant rabbit |
| Tested Applications | WBICC/IFIHC |
| WB:1:1,000-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | 58 kDa cytokeratin antibody
CK-5 antibody
CK5 antibody
Cytokeratin-5 antibody
Cytokeratin5 antibody
DDD antibody
DDD1 antibody
EBS2 antibody
epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody
K2C5_HUMAN antibody
K5 antibody
keratin 5 (epidermolysis bullosa simplex Dowling-Meara/Kobner/Weber-Cockayne types) antibody Keratin 5 antibody Keratin antibody keratin complex 2 basic gene 5 antibody keratin type II cytoskeletal 5 antibody Keratin-5 antibody Keratin5 antibody KRT 5 antibody Krt5 antibody KRT5A antibody type II cytoskeletal 5 antibody Type-II keratin Kb5 antibody |
|---|---|
| Molecular Weight(MW) | 62 kDa |
| Cellular Localization | Cytoplasm. |
| SwissProt ID | P13647 |
|---|
Application
Fig1: Western blot analysis of Cytokeratin 5 on A431 cells lysates using anti-Cytokeratin 5 antibody at 1/1,000 dilution.
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Cytokeratin 5 antibody. Counter stained with hematoxylin.| Positive Control | A431, human tonsil tissue, human liver cancer tissue, human breast carcinoma tissue. |
|---|---|
| Application Notes | WB:1:1,000-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
